Feb. 29, 2012
/PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present at two investor conferences in
Transcept management plans to present a general corporate overview at the:
Cowen Health Care Conference in
March 5, 2012
4:50 p.m. ET
; andRoth Conference in
Laguna Niguel, California
March 14, 2012
10:00 a.m. PT
A live audio webcast of each presentation will be available in the investor relations section of the Transcept website at
. An archive of the presentation will also be available in the investor section on the Transcept website for approximately 30 days following the event.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience.
Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Transcept and
are parties to a collaboration agreement for the development and commercialization of Intermezzo in
the United States
. Transcept holds all commercialization and development rights to Intermezzo outside
and has co-promotion rights to Intermezzo in
the United States
As part of its product pipeline activities, Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder.
For information about Intermezzo, please visit
For further information about Transcept, please visit
Transcept Pharmaceuticals, Inc.
Sr. Director, Corporate Communications(510) 215-3567
SOURCE Transcept Pharmaceuticals, Inc.